Human CCR9 Full Length Protein (VLP)

AIDD‑Ready
Product Number/Spec
Price
Availability
Menge
CC9-H52P3-20ug
$620.00
In Stock - Delivery in 1-2 business days
CC9-H52P3-100ug
$1,235.00
In Stock - Delivery in 1-2 business days
CC9-H52P3-500ug (250ug X 2)
$4,305.00
In Stock - Delivery in 1-2 business days
CC9-H52P3
Product Amount :
$ 0
0
Add to Cart
New Product Suggestion Request Quote
Contact Us
Contact Us
Product Amount:
$ 0
0
Add to Cart
  • Product Details
  • Data Display
  • Reviews & Citations
  • Important Statement
  • Resources
Application
  • Immunization
  • Cell based assay (FACS or functional assay)
  • Screening (ELISA)
Synonyms

C-C motif chemokine receptor 9, GPR28, CDw199, GPR-9-6, CC-CKR-9

Source

Human CCR9 Full Length Protein (VLP) (CC9-H52P3) is expressed from human 293 cells (HEK293). It contains AA Thr 2 - Leu 369 (Accession # P51686-1).

Predicted N-terminus: Asp

Molecular Characterization

*The isotype control of empty/mock VLP (Cat. No. VLP-N5213) is sold separately and not included in protein, you can follow the link for product information.

Structure

Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.

Synthesis Process

Envelope virus-like particles (eVLPs) are produced by co-expressing target membrane proteins with viral structural proteins in mammalian cells, enabling native embedding of membrane proteins into the lipid bilayer during VLP budding. This approach preserves authentic conformation, post-translational modifications, and orientation, while creating a completely detergent-free environment with repetitive multivalent display and strong immunogenicity making them ideal for immunization, binding assays in antibody discovery and screening (ELISA), and cell-based assays such as FACS, etc.

Endotoxin

Less than 1.0 EU per μg by the LAL method / rFC method.

Formulation

The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Shipping and Storage

This product is supplied and shipped on dry ice.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • The product MUST be stored at -70°C or lower upon receipt;
  • -70°C for 12 months under sterile conditions.

Background Introduction

CCR9, the receptor for CCL25, directing T cell homing to the small intestine and thymus. It is pathologically expressed in cutaneous T-cell lymphoma and acute lymphoblastic leukemia, facilitating organ-specific metastasis. Targeting CCR9 is a strategy to block lymphoma dissemination and treat inflammatory bowel disease.